Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy
Phase 2
Completed
- Conditions
- Metastatic Breast Cancer
- Registration Number
- NCT00333047
- Lead Sponsor
- Novartis
- Brief Summary
Therapeutic interventions for patients with metastatic breast cancer are aimed at prolonging survival and improving the quality of life. The objective of this trial is to assess if an initial chemotherapy followed by an endocrine therapy leads to a longer disease-free interval as compared to chemotherapy alone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Objective response rate (complete remission, partial remission,no change, progressive disease) by clinical palpation and radiologic imaging every 3 months until disease progression
- Secondary Outcome Measures
Name Time Method Time to progression and safety and toxicity during treatment